These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 18977533)

  • 1. Are cost-inclusive evaluations worth the effort?
    Herman PM; Avery DJ; Schemp CS; Walsh ME
    Eval Program Plann; 2009 Feb; 32(1):55-61. PubMed ID: 18977533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-inclusive evaluation: a banquet of approaches for including costs, benefits, and cost-effectiveness and cost-benefit analyses in your next evaluation.
    Yates BT
    Eval Program Plann; 2009 Feb; 32(1):52-4. PubMed ID: 18977532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-based evaluations of the treatment of back pain: a primer for health-care professionals.
    Johnson WG
    Spine J; 2005; 5(4):361-9. PubMed ID: 15996605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States.
    Rein DB; Wittenborn JS; Lee PP; Wirth KE; Sorensen SW; Hoerger TJ; Saaddine JB
    Ophthalmology; 2009 May; 116(5):823-32. PubMed ID: 19285730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effective primary care-based strategies to improve smoking cessation: more value for money.
    Salize HJ; Merkel S; Reinhard I; Twardella D; Mann K; Brenner H
    Arch Intern Med; 2009 Feb; 169(3):230-5; discussion 235-6. PubMed ID: 19204212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Purchasing health insurance coverage for smoking cessation treatment: employers describe the most influential information in this decision.
    Woolf NH; Burns ME; Bosworth TW; Fiore MC
    Nicotine Tob Res; 2006 Dec; 8(6):717-25. PubMed ID: 17132519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of the New South Wales adult drug court program.
    Shanahan M; Lancsar E; Haas M; Lind B; Weatherburn D; Chen S
    Eval Rev; 2004 Feb; 28(1):3-27. PubMed ID: 14750289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Qualitative cost-benefit evaluation of complex, emergent programs.
    Rogers PJ; Stevens K; Boymal J
    Eval Program Plann; 2009 Feb; 32(1):83-90. PubMed ID: 19007990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using costs in cost-effectiveness models for chronic diseases: lessons from diabetes.
    Hoerger TJ
    Med Care; 2009 Jul; 47(7 Suppl 1):S21-7. PubMed ID: 19536014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimating the short-term clinical and economic benefits of smoking cessation: do we have it right?
    Menzin J; Lines LM; Marton J
    Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):257-64. PubMed ID: 19527098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Focusing on the effectiveness side of the cost-effectiveness equation.
    Simko MD; Conklin MT
    J Am Diet Assoc; 1989 Apr; 89(4):485-7. PubMed ID: 2495319
    [No Abstract]   [Full Text] [Related]  

  • 13. What's needed for personalized therapy in smoking cessation.
    Epstein RS
    Clin Pharmacol Ther; 2008 Sep; 84(3):309-10. PubMed ID: 18714320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic analysis in hand surgery.
    Myers J; McCabe S; Gohmann S
    J Hand Surg Am; 2006 Apr; 31(4):664-8. PubMed ID: 16632063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Costing of healthcare for improving effectiveness.
    Carson D; Waugh N
    Health Bull (Edinb); 1999 Mar; 57(2):87-93. PubMed ID: 12811899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and analysis issues for economic analysis alongside clinical trials.
    Marshall DA; Hux M
    Med Care; 2009 Jul; 47(7 Suppl 1):S14-20. PubMed ID: 19536012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determining alcoholism treatment outcomes: a cost-effectiveness perspective.
    Wing DM; Gay G
    Nurs Econ; 1990; 8(4):248-55. PubMed ID: 2116600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-benefit analysis involving addictive goods: contingent valuation to estimate willingness-to-pay for smoking cessation.
    Weimer DL; Vining AR; Thomas RK
    Health Econ; 2009 Feb; 18(2):181-202. PubMed ID: 18566968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving efficiency and value in palliative care with net benefit regression: an introduction to a simple method for cost-effectiveness analysis with person-level data.
    Hoch JS
    J Pain Symptom Manage; 2009 Jul; 38(1):54-61. PubMed ID: 19615627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of pharmacy and group behavioural support smoking cessation services in Glasgow.
    Boyd KA; Briggs AH
    Addiction; 2009 Feb; 104(2):317-25. PubMed ID: 19149829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.